Adult Clinical Trials

Lung Cancer

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the Lung/ Thoracic Clinical Trials Office at 919.681.4768.

17 trials identified.

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide.
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Purpose: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.
Reference Number: 00007332
View this trial at ClinicalTrials.gov

A Phase 1 / 2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Purpose: The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Reference Number: 00056092
View this trial at ClinicalTrials.gov

SWOG S1400: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Purpose: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a non-match sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
Reference Number: 00057165
View this trial at ClinicalTrials.gov

Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Purpose: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Reference Number: 00057971
View this trial at ClinicalTrials.gov

Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Purpose: This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Reference Number: 00057973
View this trial at ClinicalTrials.gov

ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Office
Phone: 919.681.4768
Purpose: This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Reference Number: 00060199
View this trial at ClinicalTrials.gov

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A Anti-PD-L1 antibody) in Combination with Carboplatin + Nab-Paclitaxel for chemotherapy-Naive Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Jeffrey Clarke
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Purpose: This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin + Nab-paclitaxel compared with treatment with carboplatin + Nab-paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).
Reference Number: 00062549
View this trial at ClinicalTrials.gov

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Purpose: The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Reference Number: 00062555
View this trial at ClinicalTrials.gov

An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY).
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Purpose: The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a third-line and later treatment for subjects with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer (SCLC).
Reference Number: 00069666
View this trial at ClinicalTrials.gov

An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Research Clinical Trials Office
Phone: 919.681.4768
Purpose: The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy. The purpose of part 2 of this study is to compare overall survival of Nivolumab and ipilimumab combined with a short course of chemotherapy to standard of care chemotherapy in first line stage IV NSCLC.
Reference Number: 00069822
View this trial at ClinicalTrials.gov

A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Purpose: The purpose of this study is to show that maintenance therapy with nivolumab, or nivolumab plus ipilimumab followed by nivolumab alone, will prolong Overall Survival and Progression Free Survival compared with placebo in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.
Reference Number: 00070704
View this trial at ClinicalTrials.gov

Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Purpose: This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer cells. Pembrolizumab has been approved for the treatment of advanced lung cancer, but is investigational in this setting.
Reference Number: 00071629
View this trial at ClinicalTrials.gov

Duke Thoracic, Head and Neck Biomarkers and Epidemiology Study
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Qingyi Wei
Contact: Epidemiology Oncology Research Team
Phone: 919.668.5691
Reference Number: 00072532

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Purpose: This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.
Reference Number: 00073268
View this trial at ClinicalTrials.gov

Phase II trial of brigatinib after treatment with second-generation ALK inhibitors in refractory ALK rearranged NSCLC
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Thomas Stinchcombe
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Purpose: The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Reference Number: 00074492
View this trial at ClinicalTrials.gov

A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Neal Ready
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Purpose: A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
Reference Number: 00075721
View this trial at ClinicalTrials.gov

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Thomas Stinchcombe
Contact: Thoracic Oncology Clinical Trials Office
Phone: 919.681.4768
Reference Number: 00076665